The hepatitis C virus (HCV) is the most common cause of chronic viral infection in Spain and is the causative agent of the majority of cases of chronic liver disease and hepatocellular carcinoma. The prevalence of chronic hepatitis C in Spain is close to 3% of the general population. Currently, the only available treatment for chronic HCV infection, the interferons, can only induce transient remission in about 50% of treated patients and sustained remission in no more than 25%. The main goal of the present project is the design of specific ribozimes capable to cleave and inactivate the 5'NTR of the HCV genome, which is the best conserved region among and within isolates, and is essential for translation and viral replication. Once synthesized, the specificity and catalytic potential of the ribozime will be tested in transient expression systems (HeLa cells transfected with a 5'UTR-CAT co
|Effective start/end date||7/06/94 → 7/06/97|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.